MIB Agents OsteoBites and osTEAo

Osteosarcoma Webinar Series: Alanna Church, MD, Associate Director, Laboratory for Molecular Pediatric Pathology at Boston Children's Hospital, Assistant Professor of Pathology at Harvard Medical School, and Conference Cochair joins us on OsteoBites to discuss insights and higlights from the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer—From Biology t...

Osteosarcoma Webinar Series: Amy Armstrong, MD, a pediatric oncologist at Siteman Kids, joins us on OsteoBites to discuss an open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma. She will review backgr...

In an inspirational episode of osTEAo , hosts Mia and Sammy honored the memory of their late friend and co-host, Camille Wahl. As one of the original founders of the podcast, Camille envisioned osTEAo as a space where adolescents and young adults affected by osteosarcoma could share their stories and find connection. Her legacy as both a friend and an advocate continues to inspire the mission of t...

Osteosarcoma Webinar Series: Yanding Zhao, PhD to discuss how Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes. Osteosarcoma (OS) is notable for extreme chromosomal instability (CIN) and molecular heterogeneity, which have hindered therapeutic progress. To address this, the lab performed longitudinal and multi-modal profiling of 91 tumors fr...

Bio Osteosarcoma Webinar Series: Brian Ladle, MD, PhD, Assistant Professor of Oncology and Pediatrics at The Johns Hopkins University School of Medicine, joins us on OsteoBites to discuss deciphering the impact of STING agonists on the tumor microenvironment in osteosarcoma. We have learned that more engagement of the immune system and osteosarcoma results in better outcomes - even when patients a...

Dating after cancer is… complicated. Scars, body changes, medical baggage - it’s not exactly the stuff of rom-coms. In The Fault in Our Scars , OsteoWarriors Elise, Gillian, Matthew, Mia, and Sammy, get real (and a little irreverent) about navigating first dates, deciding when to drop the “I had cancer” bomb, and handling everything from awkward silences to partners who totally miss the mark. They...

Osteosarcoma Webinar Series: Amanda Marinoff, MD, a physician-scientist from UCSF will discuss clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from a working group. Despite decades of research, osteosarcoma remains one of the few pediatric cancers without validated molecular biomarkers to guide treatment. The Clinical Biomarkers for Osteosarcoma Stratification (cBOSS) initiat...

Osteosarcoma Webinar Series: Karen E. Pollok, PhD, and Pankita H. Pandya, PhD, from the Indiana University School of Medicine, join us on OsteoBites to discuss their work exploring CDK4/6i, particularly in the context of BET inhibition, as a therapeutic option for pediatric OS, regardless of RB status. Hyperactivation of cyclin-dependent kinases 4 and 6 (CDK4/6) has been identified as an actionabl...

In this powerful new episode of osTEAo, our AYA (Adolescent and Young Adult) cancer community gets real about toxic positivity - the idea that you have to "stay positive" no matter what you're going through, and while it's often well-meaning, it can leave patients feeling unseen, isolated, and emotionally shut down. In this candid and emotional conversation, OsteoWarriors share how constant encour...

Kelly Faulk, MD, a pediatric oncologist at Children's Hospital Colorado Center for Cancer and Blood Disorders, joins us on OsteoBites to review the open phase 1/1b clinical trial evaluating the combination of losartan and sunitinib in the treatment of pediatric and adult patients with relapsed or refractory osteosarcoma (NCT03900793), including preclinical rationale from canine clinical trials...

OsteoBites welcomes Yingqi Hua, MD from Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine to discuss his work on molecular subtyping of osteosarcoma, ecDNA, and more. Dr. Hua has been engaged in basic and clinical research of malignant bone tumors for more than 10 years, focusing on the individualized comprehensive treatment of advanced bone tumors, and is committed to tr...

In this special Mother's Day edition of osTEAo, Mia, Sammy, and Elise open up about a topic that’s often left unspoken but is profoundly personal—fertility and infertility within the AYA cancer community. With honesty and vulnerability, they share their experiences navigating fertility challenges in the wake of a cancer diagnosis, including the emotional strain of tough conversations with fami...

Matteo Trucco, MD, pediatric oncologist, Director of the Children’s Cancer Innovative Therapy program at the Cleveland Clinic, and chair of the MIB Agents Scientific Advisory Board joins us on OsteoBites to provide a preview of the FACTOR 2025 scientific panels in lay person terms with a brief overview of vocabulary and terms as a helpful resource for patients and families attending our FACTOR 202...

Brian Flesner, DVM, MS, DACVIM (Oncology), discusses the recently opened clinical trial studying an Autologous Cancer Vaccine with Checkpoint Inhibitor for the Treatment of Canine Osteosarcoma. The purpose of this study is to evaluate the safety and efficacy of K9-ACV, an autologous killed tumor cell vaccine combined with a novel checkpoint inhibitor (CD200AR-L), compared to standard-of-care chemo...

osTEAo co-hosts Mia and Sammy sit down with fellow OsteoWarriors Andrew and Mackenzie for a real, raw, and refreshingly honest convo about FOMO—Fear of Missing Out—as young adult cancer survivors. From missing prom and sports to navigating dating and college with a whole new perspective, these resilient humans get into what it actually feels like to rebuild a life after treatment. They talk about...

TJ Utset-Ward, MD, cirujano ortopédico del Nicklaus Children's Hospital, ofrece una descripción general de las opciones quirúrgicas y los avances en el osteosarcoma. El tratamiento del osteosarcoma consiste en una combinación de quimioterapia y cirugía para extirpar el tumor. En la década de 1980, la amputación de extremidades se utilizaba en el 80 % de los casos. Hoy en día, gracias a los ava...

The osteosarcoma community has the power to drive change in childhood cancer research! This important OsteoBites episode features Nancy Goodman, JD, Founder & Executive Director of Kids v Cancer, as she discusses how you can help advocate for the Give Kids a Chance Act—a crucial bill aimed at expanding access to novel combination therapies for kids with cancer. The Give Kids a Chance Act is bi...

Dr. Betsy Young, a physician-scientist from UCSF provides an overview of her funded work: Tumor cGAS-STING repression drives immune evasion in osteosarcoma and is therapeutically targetable via host STING activation. This work was funded by an MIB Agents 2024 OutSmarting Osteosarcoma YI Hope grant Because of Charlotte. Osteosarcoma (OS) has an immunosuppressive macrophage-rich, T-cell-depleted tum...

What does accessibility really mean, and how does it impact the daily lives of young adults navigating cancer and disability?  In this powerful episode of osTEAo,  Accessibility Wins, Fails & WTF Moments , young adult osteosarcoma survivors Mia, Sammy, Isabelle, and Inaaya open up about their personal experiences—shedding light on the challenges of inaccessible environments, the emotional weig...

Matthew Dietz, DO, MSEd joins us on OsteoBites to discuss Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: Consensus Recommendations from the Children’s Oncology Group Bone Tumour Committee. To advance the care and cure for patients with osteosarcoma and Ewing sarcoma it is necessary to safely improve the amount and usability of diagnostic biopsy material obtained. Indeed, it is antic...

Michael Lizardo, MS, PhD, a staff scientist in the Poul Sorensen laboratory at BC Cancer Agency, joins us on OsteoBites to discuss how the pharmacologic inhibition of EIF4A blocks NRF2 synthesis to prevent osteosarcoma metastasis. Dr. Lizardo shares his lab's recent findings in Clinical Cancer Research on how targeting the dysregulated mRNA translation factor eukaryotic initiation factor 4A (E...

Osteosarcoma Webinar Series: Sowmya Ramesh, PhD joins us on OsteoBites to discuss how multi-modal omics analysis identifies targetable sensory neuron circuitry that promotes sarcoma disease progression. Bone pain is a hallmark of bone cancers, including osteosarcoma (OS), mediated by skeletal-innervating peripheral afferent neurons. However, the roles of tumor-associated sensory neurons in OS beyo...

In the latest episode of osTEAo: Spilling the Tea on Osteosarcoma and AYA Cancer , young adult osteosarcoma survivors Mia, Sammy, Sloan, and Mackenzie share how their pets became their greatest sources of comfort, laughter, and unwavering support during treatment and recovery. From Sloan’s dog Sam instinctively wrapping around their leg post-surgery to Mackenzie’s pup carefully avoiding pressure o...

Alice Soragni, PhD shares information about PREMOST: an organoid-based functional PREcision Medicine trial in OSTeosarcoma (NCT06064682), a clinical trial that is studying the feasibility of using organoids for predicting drug response and guiding therapy in osteosarcoma. Patient-derived tumor organoids (PDTOs) are lab-grown replicas of tumors that closely resemble the original cancer in both stru...

Chris Thomson, DVM, DACVS-SA from Ethos Veterinary Health will discuss the Minimally Invasive Metastasectomy in Canines (MIMIC) clinical trial which will assess the feasibility and tolerability of VATS for lung metastasis and eventually deliver this care as an outpatient procedure. In addition to assessing the therapeutic benefit in canine patients, the study will also pave the way to conduct acce...